Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of IVACFLU-A/H5N1 in Healthy Adults
NCT02171819Phase 1Completed
- Sponsor
- Institute of Vaccines and Medical Biologicals
- Start
- Jun 2014
- Primary completion
- Aug 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IVACFLU-A/H5N1 in influenza A virus H5N1 subtype infection (H5N1) (3 arms), sponsored by Institute of Vaccines and Medical Biologicals. Primary endpoints: Immediate Reactions Occurring Within 60 Minutes of Administration of Any Dose, Number of Participants With at Least One Solicted Reactogenicity After Both Injections and 2 more. Started Jun 2014; status: completed.
02
Drugs
IVACFLU-A/H5N1
03
Conditions
influenza A virus H5N1 subtype infection (H5N1)
Beyond the preview
Go deeper on NCT02171819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171819.